Aurinia [AUPH] vs Regeneron [REGN] Detailed Stock Comparison
Aurinia
NASDAQ
Loading...
Regeneron
NASDAQ
Loading...
TLDR: Quick Comparison Summary
Based on 20 vital metrics comparison: Aurinia wins in 4 metrics, Regeneron wins in 15 metrics, with 0 ties. Regeneron appears stronger overall.
View Metrics Details
Vital Metrics Comparison
| Metric | Aurinia | Regeneron | Better |
|---|---|---|---|
| P/E Ratio (TTM) | 28.09 | 14.95 | Regeneron |
| Price-to-Book Ratio | 4.78 | 2.06 | Regeneron |
| Debt-to-Equity Ratio | 24.41 | 9.04 | Regeneron |
| PEG Ratio | 22.37 | 13.09 | Regeneron |
| EV/EBITDA | 16.43 | 12.21 | Regeneron |
| Profit Margin (TTM) | 23.31% | 31.37% | Regeneron |
| Operating Margin (TTM) | 28.85% | 29.64% | Regeneron |
| EBITDA Margin (TTM) | 28.85% | 29.64% | Regeneron |
| Return on Equity | 17.33% | 15.34% | Aurinia |
| Return on Assets (TTM) | 7.69% | 6.66% | Aurinia |
| Free Cash Flow (TTM) | $44.11M | $3.54B | Regeneron |
| Dividend Yield | N/A | 0.46% | N/A |
| 1-Year Return | 81.51% | -50.84% | Aurinia |
| Price-to-Sales Ratio (TTM) | 6.11 | 4.42 | Regeneron |
| Enterprise Value | $1.36B | $54.52B | Regeneron |
| EV/Revenue Ratio | 5.22 | 3.84 | Regeneron |
| Gross Profit Margin (TTM) | 89.84% | 85.58% | Aurinia |
| Revenue per Share (TTM) | $2 | $133 | Regeneron |
| Earnings per Share (Diluted) | $0.43 | $39.68 | Regeneron |
| Beta (Stock Volatility) | 1.24 | 0.33 | Regeneron |
Performance
Key Stats
Valuation
Financials
Short Interest
Dividends
Aurinia vs Regeneron Stock Performance Analysis
Loading Price Chart...
Performance Comparison
Short-term Returns
| Stock | 1D | 1W | 1M | 3M | 6M | YTD |
|---|---|---|---|---|---|---|
| Aurinia | 1.57% | 0.00% | 38.18% | 48.37% | 52.42% | 39.91% |
| Regeneron | -1.45% | 1.56% | 5.09% | -1.23% | -17.35% | -17.58% |
Long-term Returns
| Stock | 1Y | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Aurinia | 81.51% | 58.94% | -10.89% | 304.95% | 228.95% | 228.95% |
| Regeneron | -50.84% | -1.12% | -2.18% | 9.83% | 2,487.71% | 7,770.23% |
Performance & Financial Health Analysis: Aurinia vs Regeneron
| Metric | AUPH | REGN |
|---|---|---|
| Market Information | ||
| Market Cap | $1.59B | $62.88B |
| Market Cap Category | Small cap | Large cap |
| 10 Day Avg. Volume | 2,119,340 | 859,422 |
| 90 Day Avg. Volume | 2,421,113 | 933,271 |
| Last Close | $12.27 | $589.48 |
| 52 Week Range | $6.42 - $12.53 | $476.49 - $1,211.20 |
| % from 52W High | -2.08% | -51.33% |
| All-Time High | $33.97 (Nov 01, 2021) | $1,211.20 (Aug 26, 2024) |
| % from All-Time High | -63.88% | -51.33% |
| Growth Metrics | ||
| Quarterly Revenue Growth | 0.22% | 0.04% |
| Quarterly Earnings Growth | 28.80% | -0.03% |
| Financial Health | ||
| Profit Margin (TTM) | 0.23% | 0.31% |
| Operating Margin (TTM) | 0.29% | 0.30% |
| Return on Equity (TTM) | 0.17% | 0.15% |
| Debt to Equity (MRQ) | 24.41 | 9.04 |
| Cash & Liquidity | ||
| Book Value per Share (MRQ) | $2.53 | $287.55 |
| Cash per Share (MRQ) | $2.39 | $72.04 |
| Operating Cash Flow (TTM) | $92.68M | $4.74B |
| Levered Free Cash Flow (TTM) | $59.60M | $2.85B |
| Dividends | ||
| Last 12-Month Dividend Yield | N/A | 0.46% |
| Last 12-Month Dividend | N/A | $2.64 |
Valuation & Enterprise Metrics Analysis: Aurinia vs Regeneron
| Metric | AUPH | REGN |
|---|---|---|
| Price Ratios | ||
| P/E Ratio (TTM) | 28.09 | 14.95 |
| Forward P/E | 22.37 | 13.09 |
| PEG Ratio | 22.37 | 13.09 |
| Price to Sales (TTM) | 6.11 | 4.42 |
| Price to Book (MRQ) | 4.78 | 2.06 |
| Market Capitalization | ||
| Market Capitalization | $1.59B | $62.88B |
| Enterprise Value | $1.36B | $54.52B |
| Enterprise Value Metrics | ||
| Enterprise to Revenue | 5.22 | 3.84 |
| Enterprise to EBITDA | 16.43 | 12.21 |
| Risk & Other Metrics | ||
| Beta | 1.24 | 0.33 |
| Book Value per Share (MRQ) | $2.53 | $287.55 |
Financial Statements Comparison: Aurinia vs Regeneron
Financial Metrics
Loading Financial Charts...
Revenue
EBITDA
Operating Margin
Free Cash Flow
Long Term Debt
Profit Margin
Current Ratio
Operating Cash Flow
Income Statement (MRQ)
| Metric (MRQ) | AUPH | REGN |
|---|---|---|
| Revenue/Sales | $62.47M | $3.03B |
| Cost of Goods Sold | $8.57M | $464.30M |
| Gross Profit | $53.89M | $2.56B |
| Research & Development | $5.74M | $1.34B |
| Operating Income (EBIT) | $23.38M | $591.70M |
| EBITDA | $31.81M | $900.90M |
| Pre-Tax Income | $24.35M | $905.00M |
| Income Tax | $1.01M | $96.30M |
| Net Income (Profit) | $23.34M | $808.70M |
Balance Sheet & Liquidity Metrics (MRQ)
| Metric (MRQ) | AUPH | REGN |
|---|---|---|
| Cash & Equivalents | $66.43M | $3.09B |
| Total Current Assets | $405.76M | $17.57B |
| Total Current Liabilities | $68.41M | $3.57B |
| Long-Term Debt | $62.37M | $2.70B |
| Total Shareholders Equity | $350.19M | $29.39B |
| Retained Earnings | $-913.23M | $32.38B |
| Property, Plant & Equipment | $87.58M | N/A |
Cash Flow Statement Comparison (MRQ)
| Metric (MRQ) | AUPH | REGN |
|---|---|---|
| Operating Cash Flow | $19.52M | $1.36B |
| Capital Expenditures | $-17,000 | N/A |
| Free Cash Flow | $1.28M | $773.60M |
| Debt Repayment | $-2.77M | N/A |
| Common Stock Repurchase | $-46.92M | $-1.05B |
Short Interest & Institutional Ownership Analysis
| Metric | AUPH | REGN |
|---|---|---|
| Shares Short | 9.16M | 2.29M |
| Short Ratio | 4.41 | 2.55 |
| Short % of Float | 0.08% | 0.02% |
| Average Daily Volume (10 Day) | 2,119,340 | 859,422 |
| Average Daily Volume (90 Day) | 2,421,113 | 933,271 |
| Shares Outstanding | 140.88M | 109.62M |
| Float Shares | 128.06M | 97.89M |
| % Held by Insiders | 0.07% | 0.02% |
| % Held by Institutions | 0.45% | 0.91% |
Dividend Analysis & Yield Comparison: Aurinia vs Regeneron
| Metric | AUPH | REGN |
|---|---|---|
| Last 12-Month Dividend | N/A | $2.64 |
| Last 12-Month Dividend Yield | N/A | 0.46% |
| 3-Year Avg Annual Dividend | N/A | $0.88 |
| 3-Year Avg Dividend Yield | N/A | 0.14% |
| 3-Year Total Dividends | N/A | $2.64 |
| Ex-Dividend Date | N/A | Aug 18, 2025 |